PK ! 1m\V! V! xl/worksheets/sheet1.xml
0
1
23
4493105498533
5301543313578
671456
8191562183499
99072677976
104818236379
117960
1235821270
1328022575
1474500
153632048
164590757791
17
18-33885-39899
192088-5181
20794633
21-31003-44447
221490413344
23359-108173
2414545121517
25-7839-6450
266706115067
27
280.050.78
290.040.78
30
28148013147180
29151220147956
PK ! '
0
xl/worksheets/sheet2.xml
31
1
23
2414545121517
25-7839-6450
266706115067
32
33-6366-5135
3420772-62658
35-730234456
367104-33337
371381081730
PK ! s=F6 6 xl/worksheets/sheet3.xml
38
3940
41
42
43452097341378
4437175743
45530600638895
46497008490649
477513773467
4811021407
4915596611551539
50471165477754
51522758522814
5212629541304626
533239633947
542411024792
55674659541
56758676
571956122344
5839600704006033
59
60
61574322611867
622981744228
6366376474
6428833978
6530201794
6671000
67201007561
68636779676902
6927282122735264
703682836440
712843530182
722230823049
73618712318
74760193
7520611584
766378983365
7729435042972395
78
791307911804
80
8177
8214851475
8315221522
84634484628413
85-280115-286821
86-34361-41318
87323015303271
884369341661
89366708344932
9039600704006033
PK ! _$3 3 xl/worksheets/sheet4.xml
91
1
23
92
2414545121517
93
945554958083
95-19705514
9621832004
9772416
9853304539
991602115200
10014311266
101
45108385-60893
46-20283-2778
1027-110069
103602-26383
4830176
104-3722634839
10532603695
10614812849026
107
108-11776-7367
109-9177
1107-1050
1117-253625
112-12693-262042
113
1147180000
115-23630-7158
1167300000
1177-4102
1186765
119-2102-503
120-93-263
121-10007
122-26149467979
123-593-860
124108693254103
125347121152822
126455814406925
127452097405238
12837171687
126455814406925
129
1302991735386
1317333430
132
13313436033
1359757134
PK ! 73C. C. xl/worksheets/sheet5.xml
136
137138139140141142143144
145146145146
14714767414751521171522628413-286821-413184166134493211804
2477777670676043127491796
148777777-3139-3227-63667
987777533077753307
1492442776777-34316767
150797877647-113-2108-21497
1517777771024310529207727
1527777777-9236-9236-521
15314871514851521171522634484-280115-343614369336670813079
PK ! 4Px, , xl/worksheets/sheet6.xml
137138139140141142143144
145146145146
15414707014701521171522606966-377880-68114778346788134
2477777115067753621204291088
155777777-2525-2610-51357
987777453977745397
1491777577757
1562402779077-602-5107
157777777-30812-31846-626587
15877777777711475
15914731114721521171522611600-262813-334058508240345812563
PK ! ,,q q xl/worksheets/sheet7.xml
160
161254000
16235033
1636855
1641000
165-2640
166294248
PK ! tb
b
xl/worksheets/sheet8.xml
167
168
4546702
4671908
4711316
4861
1695278
51103679
52130800
545544
170375288
6162489
1051532
725544
17169565
7911475
172294248
PK !
^P P xl/worksheets/sheet9.xml
173174
17566700176
17722000178
17928600180
18113000182
183500184
130800
PK ! "HIӵ" " xl/worksheets/sheet10.xml
185
1
23
186
187591313253
18810670387481
189-794115824
19096291101575
1913531129679
1921945823536
1931903015966
194655717229
195817810067
1961287815245
197973121746
198399985
199312508352586
200
2011679614227
1906771168311
197114245439
2029593187977
203
2044549931586
2053107221378
20651793413
20729161593
2088466657970
209493105498533
PK ! +
xl/worksheets/sheet11.xml
210211212213
21462880422690174984131088
215727258250482478628770
216-838304-25402-25758-26852
15351775822336174012133006
PK ! Vq q xl/worksheets/sheet12.xml
217
218
23
219
266706115067
220
221148013147180
222
223792230
2242415546
225151220147956
226
280.050.78
290.040.78
PK ! \= xl/worksheets/sheet13.xml
218
23
223347-1683-1
2275124-23054-2
228152117-3152117-3
PK ! j
xl/worksheets/sheet14.xml
229
230231
23210721381291785
233-1444-1396
234-517758-628804
235-22336-22690
236-541538-652890
45530600638895
PK ! x_ xl/worksheets/sheet15.xml
237
230231
238205874209180
2395163340937
240239501240532
241497008490649
PK ! ~r r xl/worksheets/sheet16.xml
242
243
39244245246247
248
2493313113433131134
2501450013414500134
40
248
249539037539037
250140077140077
PK ! N xl/worksheets/sheet17.xml
251
3940
252253254253254
25576331317653903
PK ! K, xl/worksheets/sheet18.xml
256
230231
257522814419504
2587103679
259-56-369
260522758522814
PK ! xl/worksheets/sheet19.xml
261
3940
262263264265263264265
266
2678.8000000000000011149245-3601747890711153096-328587824509
2685.5133800-3931294488133800-33078100722
2361283045-3994868835591286896-361665925231
26937939573793953793957379395
2701662440-39948612629541666291-3616651304626
PK ! (D xl/worksheets/sheet20.xml
271
272125091
273155162
274143395
275136910
27697937
277225064
244883559
PK ! Oy xl/worksheets/sheet21.xml
278
279280200281282283
43125089593184666134493105
518529848198680477301543
812721047733166197191562
91876219881137043837990726
1036117120657748182
1235827773582
137793118712802
158077283363
28468669157871984-4053345907
PK ! b1R* * xl/worksheets/sheet22.xml
285280200286287288
43525868797757970134498533
521886547818468957313578
61456771456
813226540159110757183499
91662320942107882962377976
102903473457736379
11960777960
1212655771270
1377725752575
1425002000774500
15467720022048
284818379867287-3420057791
PK ! E xl/worksheets/sheet23.xml
289
290
291
29229323
294295134134
2962971134
PK ! bܬ
xl/worksheets/sheet24.xml
298
290
291
29229323
299300134134
30130232
303304134134
PK ! v xl/worksheets/sheet25.xml
305
306307308
309-78327764-68
310-6643-34560-41203
311-22-25-47
312-14497-26821-41318
310-3139102437104
311-52-95-147
313-17688-16673-34361
PK ! xl/worksheets/sheet26.xml
314
218
23
4493105498533
5301543313578
671456
8191562183499
99072677976
104818236379
117960
1235821270
1328022575
1474500
153632048
164590757791
21-31003-44447
221490413344
23359-108173
2414545121517
PK ! 00 0 xl/worksheets/sheet27.xml
186
218
23
4312508352586
5185298218865
671456
8127210132265
91876216623
103611729034
117960
1235821265
1472500
158046
166866981837
PK ! +I2
2
xl/worksheets/sheet28.xml
200
218
23
49593187977
54819847818
84773340159
91988120942
10120657345
1275
1472000
16157879867
PK ! B$ $ xl/worksheets/sheet29.xml
278
218
23
48466657970
56804746895
81661911075
91370410788
139317
161984287
PK ! 4s
s
xl/worksheets/sheet30.xml
315
218
23
316
31714812849026
318-12693-262042
319-26149467979
320-593-860
124108693254103
PK ! . xl/worksheets/sheet31.xml
321
322
323244324325326327
3281000007000030000134134
PK ! ܪh xl/worksheets/sheet32.xml
329
330331
3.1332
10.1333
10.2334
31.1335
31.2335
31.3336
32.1337
32.2337
32.3338
101339
104340
PK ! X X xl/worksheets/sheet33.xml
341
342
PK ! bY Y xl/worksheets/sheet34.xml
343344
345346
PK ! V xl/worksheets/sheet35.xml
347348
PK ! g, xl/worksheets/sheet36.xml
349350
PK ! XOԠ xl/worksheets/sheet37.xml
351352
PK ! bE@ xl/worksheets/sheet38.xml
353354
PK ! SY xl/worksheets/sheet39.xml
355356
PK ! QX[ xl/worksheets/sheet40.xml
357358
PK ! *O xl/worksheets/sheet41.xml
359360
PK ! E xl/worksheets/sheet42.xml
343361
PK ! d6~Y Y xl/worksheets/sheet43.xml
362363
364365
PK ! [ xl/worksheets/sheet44.xml
366367
PK ! .c- xl/worksheets/sheet45.xml
343368
PK ! o xl/worksheets/sheet46.xml
345369
PK ! \ xl/worksheets/sheet47.xml
370371
PK ! 89^ xl/worksheets/sheet48.xml
343372
PK ! xl/worksheets/sheet49.xml
345373
PK ! ';h xl/worksheets/sheet50.xml
347374
PK ! 37 xl/worksheets/sheet51.xml
349375
PK ! H=lǠ xl/worksheets/sheet52.xml
343376
PK ! ¨! xl/worksheets/sheet53.xml
345377
PK ! 飜 xl/worksheets/sheet54.xml
378
379380381
382
383
PK ! 8g xl/worksheets/sheet55.xml
378
379380384
385
386
PK ! ] xl/worksheets/sheet56.xml
378
379380387
388
389
PK ! m xl/worksheets/sheet57.xml
390
379380381
382
391
392
PK ! xl/worksheets/sheet58.xml
390
379380384
385
393
392
PK !
xl/worksheets/sheet59.xml
390
379380387
388
394
395
PK ! r xl/workbook.xml
PK ! _Ji Ji xl/sharedStrings.xml
Consolidated Statements of OperationsThree Months Ended March 31,20212020Net revenueCost of goods soldCost of goods sold impairment charges—Gross profitSelling, general and administrativeResearch and developmentIn-process research and development impairment chargesIntellectual property legal development expensesAcquisition, transaction-related and integration expensesCharges related to legal matters, netRestructuring and other chargesOperating incomeOther (expense) income:Interest expense, netForeign exchange gain (loss), netOther income, netTotal other expense, netIncome before income taxesProvision for (benefit from) income taxesNet incomeLess: Net income attributable to non-controlling interestsNet income attributable to Amneal Pharmaceuticals, Inc.Net income per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:BasicDilutedWeighted-average common shares outstanding:Consolidated Statements of Comprehensive IncomeOther comprehensive income (loss):Foreign currency translation adjustments arising during the periodUnrealized gain (loss) on cash flow hedge, net of taxLess: Other comprehensive (income) loss attributable to non-controlling interestsOther comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc.Comprehensive income attributable to Amneal Pharmaceuticals, Inc.Consolidated Balance SheetsMarch 31, 2021December 31, 2020AssetsCurrent assets:Cash and cash equivalentsRestricted cashTrade accounts receivable, netInventoriesPrepaid expenses and other current assetsRelated party receivablesTotal current assetsProperty, plant and equipment, netGoodwillIntangible assets, netOperating lease right-of-use assetsOperating lease right-of-use assets - related partyFinancing lease right-of-use assetsFinancing lease right-of-use assets - related partyOther assetsTotal assetsLiabilities and Stockholders' EquityCurrent liabilities:Accounts payable and accrued expensesCurrent portion of long-term debt, netCurrent portion of operating lease liabilitiesCurrent portion of operating and financing lease liabilities - related partyCurrent portion of financing lease liabilitiesCurrent portion of note payable - related partyRelated party payable - short termTotal current liabilitiesLong-term debt, netNote payable - related partyOperating lease liabilitiesOperating lease liabilities - related partyFinancing lease liabilitiesFinancing lease liabilities - related partyRelated party payable - long termOther long-term liabilitiesTotal long-term liabilitiesCommitments and contingencies (Notes 5 and 14)Redeemable non-controlling interestsStockholders' EquityPreferred stock, $0.01 par value, 2,000 shares authorized; none issued at both March 31, 2021 and December 31, 2020Class A common stock, $0.01 par value, 900,000 shares authorized at both March 31, 2021 and December 31, 2020; 148,715 and 147,674 shares issued at March 31, 2021 and December 31, 2020, respectivelyClass B common stock, $0.01 par value, 300,000 shares authorized at both March 31, 2021 and December 31, 2020; 152,117 shares issued at both March 31, 2021 and December 31, 2020Additional paid-in capitalStockholders' accumulated deficitAccumulated other comprehensive lossTotal Amneal Pharmaceuticals, Inc. stockholders' equityNon-controlling interestsTotal stockholders' equityTotal liabilities and stockholders' equityConsolidated Statements of Cash FlowsCash flows from operating activities:Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortizationUnrealized foreign currency (gain) lossAmortization of debt issuance costs and discountIntangible asset impairment chargesStock-based compensationInventory provisionOther operating charges and credits, netChanges in assets and liabilities:Income taxes receivable associated with the CARES ActPrepaid expenses, other current assets and other assetsAccounts payable, accrued expenses and other liabilitiesRelated party payablesNet cash provided by operating activitiesCash flows from investing activities:Purchases of property, plant and equipmentDeposits for future acquisition of property, plant, and equipmentAcquisition of intangible assetsAcquisitions, net of cash acquiredNet cash used in investing activitiesCash flows from financing activities:Proceeds from issuance of debtPayments of principal on debt, financing leases and otherNet borrowings on revolving credit facilityPayments of deferred financing costsProceeds from exercise of stock optionsEmployee payroll tax withholding on restricted stock unit vestingPayments of principal on financing lease - related partyRepayment of related party noteNet cash (used in) provided by financing activitiesEffect of foreign exchange rate on cashNet increase in cash, cash equivalents, and restricted cashCash, cash equivalents, and restricted cash - beginning of periodCash, cash equivalents, and restricted cash - end of periodCash and cash equivalents - end of periodRestricted cash - end of periodSupplemental disclosure of cash flow information:Cash paid for interestCash paid for income taxes, netSupplemental disclosure of non-cash investing and financing activity:Notes payable for acquisitions - related party$—Tax distribution to non-controlling interestsConsolidated Statements of Changes in Stockholders' EquityClass A Common
StockClass B Common
StockAdditional
Paid-in CapitalStockholders'
Accumulated DeficitAccumulated
Other
Comprehensive LossNon-
Controlling InterestsTotal EquityRedeemable Non-Controlling InterestsSharesAmountBalance at January 1, 2021Foreign currency translation
adjustmentExercise of stock optionsRestricted stock unit vesting,
net of shares withheld to
cover payroll taxesUnrealized gain on cash flow
hedge, net of taxTax distributionBalance at March 31, 2021Balance at January 1, 2020Foreign currency translation
adjustmentRestricted stock unit vesting,
net of shares withheld to
cover payroll taxesUnrealized loss on cash flow
hedge, net of taxNon-controlling interests from
Rondo transactionBalance at March 31, 2020AvKARE and R&S AcquisitionsCashSellers Notes (1)Settlement of Amneal trade accounts receivable from R&S (2)Short-Term Seller Note (3)Working capital adjustment (4)Fair value consideration transferredBusiness Combinations,Final Fair Values as of
January 31, 2020Property, plant and equipmentTotal assets acquiredTotal liabilities assumedFair value of consideration transferredFair ValuesWeighted-Average
Useful LifeGovernment licenses7 yearsGovernment contracts4 yearsNational contracts5 yearsCustomer relationships10 yearsTrade name6 yearsDisaggregated RevenueGenericsAnti-InfectiveHormonalAntiviral (1)Central Nervous SystemCardiovascular SystemGastroenterologyOncologyMetabolic Disease/EndocrineRespiratoryDermatologyOther therapeutic classesInternational and otherTotal Generics net revenueSpecialtyHormonal/MetabolicTotal Specialty net revenueAvKARE (2)DistributionGovernment LabelInstitutionalOtherTotal AvKARE net revenueTotal net revenueContract
Charge - Backs
and Sales
Volume
AllowancesCash Discount
AllowancesAccrued
Returns
AllowanceAccrued
Medicaid and
Commercial
RebatesBalance at December 31, 2020Provision related to sales recorded in the periodCredits/payments issued during the period7. Earnings per ShareThree Months Ended
March 31,Numerator:Denominator:Weighted-average shares outstanding - basicEffect of dilutive securities:Stock optionsRestricted stock unitsWeighted-average shares outstanding - dilutedNet earnings per share attributable to Amneal Pharmaceuticals, Inc.'s class A common stockholders:Performance stock unitsShares of class B common stock9. Trade Accounts Receivable, NetMarch 31,
2021December 31,
2020Gross accounts receivableAllowance for credit lossesContract charge-backs and sales volume allowancesCash discount allowancesSubtotal10. InventoriesRaw materialsWork in processFinished goodsTotal inventoriesAssets and Liabilities Measured at Fair Value on a Recurring BasisFair Value Measurement Based onTotalQuoted
Prices in
Active
Markets
(Level 1)Significant
Other
Observable
Inputs
(Level 2)Significant
Unobservable
Inputs
(Level 3)LiabilitiesInterest rate swap (1)Deferred compensation plan liabilities (2)Interest Rate Derivative Cash Flow HedgeDerivatives Designated as Hedging InstrumentsBalance Sheet
ClassificationFair ValueVariable-to-fixed interest rate swap13. Goodwill and Intangible AssetsBalance, beginning of periodGoodwill acquired during the periodCurrency translationBalance, end of periodNote 3. Acquisitions and DivestituresWeighted-Average
Amortization Period
(in years)CostAccumulated
AmortizationNetAmortizing intangible assets:Product rightsOther intangible assetsIn-process research and developmentTotal intangible assetsFuture
AmortizationRemainder of 20212022202320242025ThereafterAvKAREThree Months Ended March 31, 2021Generics (1)AvKARE (1)Corporate and OtherTotal CompanyOperating income (loss)Three Months Ended March 31, 2020AvKARE (1,2)Corporate
and OtherTotal
CompanyAgreements with Kashiv Not Affected by the Acquisition of KSPAmounts in millionsResearch and development expenses for three months ended March 31,ProductsAgreement DateFilgrastim and PEG-Filgrastim (1)October 2017Ganirelix Acetate and Cetrorelix acetate (2)August 2020Agreements with Kashiv Included in the Acquisition of KSPLevothyroxine Sodium (1)June 2019K127 (2)November 2019Posaconazole (3)May 2020Changes in Accumulated Other Comprehensive Loss by Component (in thousands):Foreign
currency
translation
adjustmentUnrealized
gain (loss) on cash
flow hedge, net
of taxAccumulated
other
comprehensive
lossBalance December 31, 2019Other comprehensive loss before reclassificationReallocation of ownership interestsBalance December 31, 2020Balance March 31, 2021Consolidated ResultsCash FlowsCash provided by (used in):Operating activitiesInvesting activitiesFinancing activitiesEffect of exchange rate changes on cashItem 7. Managements Discussion and Analysis of Financial Condition and Results of OperationsPayments Due by PeriodContractual ObligationsLess
Than 1
Year1-3
Years3-5
YearsMore
Than 5
YearsKashiv Specialty Pharmaceuticals, LLC acquisitionItem 6. ExhibitsExhibit No.Description of DocumentSecond Amended and Restated Certificate of Incorporation of Amneal Pharmaceuticals, Inc. adopted as of May 5, 2021. *Employment Agreement by and among Amneal Pharmaceuticals, Inc. and Joseph Todisco , dated as of July 29, 2020. † *Employment Agreement by and among Amneal Pharmaceuticals, Inc. and Nikita Shah, dated as of July 29, 2020. †*Certification of the Co - Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 200 2.*Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 200 2.*Certification of the Co - Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 formatted in inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Operations for each of the three months ended March 31, 2021 and 2020, (ii) Consolidated Statements of Comprehensive Income for each of the three months ended March 31, 2021 and 2020, (iii) Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020, (v) Consolidated Statements of Changes in Stockholders' Equity for each of the three months ended March 31, 2021 and 2020 and (vi) Notes to Consolidated Financial Statements.*Cover Page Interactive Data File – The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 is formatted in Inline XBRL (included as Exhibit 101).SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMNEAL PHARMACEUTICALS, INC.Class A Common Stock and Class B Common Stock . Each holder of Class A Common Stock and Class B Common Stock shall be entitled to one vote for each share of Class A Common Stock or Class B Common Stock held of record by such holder. Except as required by law or as otherwise expressly provided for in this Restated Certificate of Incorporation, the holders of Class A Common Stock and Class B Common Stock shall vote together as a single class on all matters upon which such holders are entitled to vote.b)whether the shares of such series shall have voting rights or powers, in addition to any voting rights required by law, and, if so, the terms of such voting rights or powers, which may be full or limited;c)the dividends, if any, payable on such series, whether any such dividends shall be cumulative, and, if so, from what dates, the conditions and dates upon which such dividends shall be payable, and the preference or relation which such dividends shall bear to the dividends payable on any shares of stock or any other class or any other series of this class;d)whether the shares of such series shall be subject to redemption by the Corporation and, if so, the times, prices and other conditions of such redemption;e)the amount or amounts payable upon shares of such series upon, and the rights of the holders of such series in, the voluntary or involuntary liquidation, dissolution or winding up, or upon any distribution of the assets, of the Corporation;f)whether the shares of such series shall be subject to the operation of a retirement or sinking fund and, if so, the extent to and manner in which any such retirement or sinking fund shall be applied to the purchase or redemption of the shares of such series for retirement or other corporate purposes and the terms and provisions relative to the operation thereof;g)whether the shares of such series shall be convertible into, or exchangeable for, shares of capital stock of any other class or any other series of this class or any other securities and, if so, the price or prices or the rate or rates of conversion or exchange and the method, if any, of adjusting the same, and any other terms and condition or exchange;h)the limitations and restrictions, if any, to be effective while any shares of such series are outstanding upon the payment of dividends or the making of other distributions on, and upon the purchase, redemption or other acquisition by the Corporation of, the Common Stock or shares of capital stock of any other class or any other series of this class;i)the conditions or restrictions, if any, to be effective while any shares of such series are outstanding upon the creation of indebtedness of the Corporation upon the issue of any additional stock, including additional shares of such series or of any other series of this class or of any other class; andj)any other powers, designations, preferences and relative, participating, optional or other special rights, and any qualifications, limitations or restrictions thereof.Notwithstanding the foregoing, unless otherwise determined pursuant to Section 2 of this ARTICLE THIRTEENTH, no advance shall be made by the Corporation to an executive officer of the Corporation (except by reason of the fact that such executive officer is or was a director of the Corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i) by a majority vote of directors who were not parties to the proceeding, even if not a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or such directors so direct, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the Corporation.i.one or more officers or employees of the Corporation whom the director or executive officer believed to be reliable and competent in the matters presented;ii.counsel, independent accountants or other persons as to matters which the director or executive officer believed to be within such person’s professional competence; andiii.with respect to a Director, a committee of the Board upon which such director does not serve, as to matters within such Committee’s designated authority, which committee the director believes to merit confidence; so long as, in each case, the director or executive officer acts without knowledge that would cause such reliance to be unwarranted.The termination of any proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal proceeding, that he had reasonable cause to believe that his conduct was unlawful.The provisions of this ARTICLE THIRTEENTH shall not be deemed to be exclusive or to limit in any way the circumstances in which a person may be deemed to have met the applicable standard of conduct set forth by the DGCL.a)The term “Corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, member, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this ARTICLE THIRTEENTH with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued;The term “other enterprises” shall include employee benefit plans;The term “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan;References to “serving at the request of the Corporation” shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants or beneficiaries; andA person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Corporation” as referred to in this ARTICLE THIRTEENTH.“ Amneal ” shall mean Amneal Pharmaceuticals, Inc.“ Person ” shall mean an individual, a firm, a corporation, a partnership, a limited liability company, an association, a joint venture, a joint stock company, a trust, an unincorporated organization or similar company, or any other entity.SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002May 7, 2021By:/s/ Chirag PatelChirag PatelPresident and Co-Chief Executive Officer
(Co-Principal Executive Officer)/s/ Chintu PatelChintu PatelCo-Chief Executive Officer
(Co-Principal Executive Officer)/s/ Anastasios KonidarisAnastasios KonidarisExecutive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002President and Co-Chief Executive Officer(Co-Principal Executive Officer)Co-Chief Executive OfficerExecutive Vice President and Chief Financial Officer(Principal Financial and Accounting Officer)PK ! AF
F
docProps/app.xml
Microsoft Excel0falseWorksheets59operationscomprehensive incomeconsolidated balance sheetscash flowschanges in stockholders eqchanges in stockholders eq-1avkare and rs acquisitionsbusiness combinationsbusiness combinations-1disaggregated revenuedisaggregated revenue-17 earnings per share7 earnings per share-19 trade accounts receivabl10 inventoriesassets and liabilities meainterest rate derivative c13 goodwill and intangiblenote 3 acquisitions and dinote 3 acquisitions and di-1avkareavkare-1agreements with kashiv notagreements with kashiv incchanges in accumulated othconsolidated resultsgenericsspecialtyavkare-2cash flows-1item 7 managements discussitem 6 exhibitssecond amended and restatesecond amended and restate-1second amended and restate-2second amended and restate-3second amended and restate-4second amended and restate-5second amended and restate-6second amended and restate-7second amended and restate-8second amended and restate-9second amended and restate-10second amended and restate-11second amended and restate-12second amended and restate-13second amended and restate-14second amended and restate-15second amended and restate-16second amended and restate-17second amended and restate-18second amended and restate-19second amended and restate-20section 302 of the sarbanesection 302 of the sarbane-1section 302 of the sarbane-2section 906 of the sarbanesection 906 of the sarbane-1section 906 of the sarbane-2falsefalsefalse12.0000PK ! ٢`P P docProps/core.xml
2021-05-07T20:31:53Z2021-05-07T20:31:53ZPK ! >u# # [Content_Types].xml
PK ! #f f
xl/styles.xml
PK ! FTR R xl/theme/theme1.xml
PK ! IK K _rels/.rels
PK ! GWq# # xl/_rels/workbook.xml.rels
PK ! 1m\V! V! xl/worksheets/sheet1.xmlPK ! '
0
! xl/worksheets/sheet2.xmlPK ! s=F6 6 / xl/worksheets/sheet3.xmlPK ! _$3 3 `f xl/worksheets/sheet4.xmlPK ! 73C. C. P xl/worksheets/sheet5.xmlPK ! 4Px, , xl/worksheets/sheet6.xmlPK ! ,,q q xl/worksheets/sheet7.xmlPK ! tb
b
z xl/worksheets/sheet8.xmlPK !
^P P
xl/worksheets/sheet9.xmlPK ! "HIӵ" " xl/worksheets/sheet10.xmlPK ! +
5 xl/worksheets/sheet11.xmlPK ! Vq q @ xl/worksheets/sheet12.xmlPK ! \= fO xl/worksheets/sheet13.xmlPK ! j
X xl/worksheets/sheet14.xmlPK ! x_ b xl/worksheets/sheet15.xmlPK ! ~r r j xl/worksheets/sheet16.xmlPK ! N } xl/worksheets/sheet17.xmlPK ! K, x xl/worksheets/sheet18.xmlPK ! xl/worksheets/sheet19.xmlPK ! (D ˨ xl/worksheets/sheet20.xmlPK ! Oy xl/worksheets/sheet21.xmlPK ! b1R* * xl/worksheets/sheet22.xmlPK ! E a xl/worksheets/sheet23.xmlPK ! bܬ
! xl/worksheets/sheet24.xmlPK ! v B xl/worksheets/sheet25.xmlPK ! xl/worksheets/sheet26.xmlPK ! 00 0 " xl/worksheets/sheet27.xmlPK ! +I2
2
2 xl/worksheets/sheet28.xmlPK ! B$ $ R@ xl/worksheets/sheet29.xmlPK ! 4s
s
K xl/worksheets/sheet30.xmlPK ! . WV xl/worksheets/sheet31.xmlPK ! ܪh w` xl/worksheets/sheet32.xmlPK ! X X kp xl/worksheets/sheet33.xmlPK ! bY Y s xl/worksheets/sheet34.xmlPK ! V w xl/worksheets/sheet35.xmlPK ! g, az xl/worksheets/sheet36.xmlPK ! XOԠ 8} xl/worksheets/sheet37.xmlPK ! bE@ xl/worksheets/sheet38.xmlPK ! SY xl/worksheets/sheet39.xmlPK ! QX[ xl/worksheets/sheet40.xmlPK ! *O xl/worksheets/sheet41.xmlPK ! E k xl/worksheets/sheet42.xmlPK ! d6~Y Y B xl/worksheets/sheet43.xmlPK ! [ ґ xl/worksheets/sheet44.xmlPK ! .c- xl/worksheets/sheet45.xmlPK ! o xl/worksheets/sheet46.xmlPK ! \ W xl/worksheets/sheet47.xmlPK ! 89^ . xl/worksheets/sheet48.xmlPK ! xl/worksheets/sheet49.xmlPK ! ';h ܢ xl/worksheets/sheet50.xmlPK ! 37 xl/worksheets/sheet51.xmlPK ! H=lǠ xl/worksheets/sheet52.xmlPK ! ¨! a xl/worksheets/sheet53.xmlPK ! 飜 8 xl/worksheets/sheet54.xmlPK ! 8g xl/worksheets/sheet55.xmlPK ! ] xl/worksheets/sheet56.xmlPK ! m xl/worksheets/sheet57.xmlPK ! xl/worksheets/sheet58.xmlPK !
xl/worksheets/sheet59.xmlPK ! r xl/workbook.xmlPK ! _Ji Ji ) xl/sharedStrings.xmlPK ! AF
F
F docProps/app.xmlPK ! ٢`P P T docProps/core.xmlPK ! >u# # V [Content_Types].xmlPK ! #f f
Zz xl/styles.xmlPK ! FTR R xl/theme/theme1.xmlPK ! IK K n _rels/.relsPK ! GWq# # xl/_rels/workbook.xml.relsPK D D ,